Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

Discussion:P1101 appears to be a well-tolerated therapy that has shown a durable clinical improvement in 37.5% in a small study. These results, along with historic data suggesting possible reduction in clonal burden, suggest that ongoing studies are warranted to further understand the clinical benefit of P1101 in MF.DisclosuresPalmer: Novartis: Research Funding. Zimmerman: PharmaEssentia: Employment. Zagrijtschuk: PharmaEssentia: Employment. Mesa: Gilead: Research Funding; CTI: Research Funding; Celgene: Research Funding; Ariad: Consultancy; Promedior: Research Funding; Incyte: Research Funding; Galena: Consultancy; Novartis: Consultancy.

Source: Blood - November 21, 2018 Category: Hematology Authors: Palmer, J., Kosiorek, H. E., Zimmerman, C., Zagrijtschuk, O., Camoriano, J., Mesa, R. A. Tags: 634. Myeloproliferative Syndromes: Clinical Source Type: research